{"id":575179,"date":"2026-03-13T00:00:00","date_gmt":"2026-03-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0040-2026-biopharma-myasthenia-gravis-unmet-need-unmet-need-generalized-myasthenia-gravis-us-eu\/"},"modified":"2026-04-22T23:10:22","modified_gmt":"2026-04-22T23:10:22","slug":"unnecg0040-2026-biopharma-myasthenia-gravis-unmet-need-unmet-need-generalized-myasthenia-gravis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0040-2026-biopharma-myasthenia-gravis-unmet-need-unmet-need-generalized-myasthenia-gravis-us-eu\/","title":{"rendered":"Myasthenia Gravis &#8211; Unmet Need &#8211; Unmet Need &#8211; Generalized Myasthenia Gravis (US\/EU)"},"content":{"rendered":"<p>Myasthenia gravis (<abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr>) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (g<abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr>) often involves anti-acetylcholine receptor (antiAChR) or anti<abbr data-abbreviation-entity=\"10606\" title=\"muscle-specific tyrosine kinase\">MuSK<\/abbr> antibodies, though some patients remain seronegative and may present with ocularonly symptoms. The <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr>, <abbr data-abbreviation-entity=\"5851\" title=\"European Commission\">EC<\/abbr>, and <abbr data-abbreviation-entity=\"5848\" title=\"Medicines and Healthcare Products Regulatory Agency (U.K.)\">MHRA<\/abbr> have approved six therapies for <abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr>: eculizumab (Alexion \/ AstraZeneca\u2019s Soliris, biosimilars), efgartigimod (Argenx\u2019s Vyvgart \/ Vyvgart Hytrulo \/ <abbr data-abbreviation-entity=\"4958\" title=\"subcutaneous\">SC<\/abbr>), ravulizumab (Alexion \/ AstraZeneca\u2019s Ultomiris), zilucoplan (<abbr data-abbreviation-entity=\"10876\" title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s Zilbrysq), rozanolixizumab (<abbr data-abbreviation-entity=\"10876\" title=\"Union Chimique Belge\">UCB<\/abbr>\u2019s Rystiggo), and nipocalimab (Johnson &#038; Johnson\u2019s Imaavy). This report examines how key clinical (e.g., change in <span><abbr data-abbreviation-entity=\"10946\" title=\"Quantitative Myasthenia Gravis\">QMG<\/abbr><\/span><span>, <\/span><span><abbr data-abbreviation-entity=\"10947\" title=\"Myasthenia Gravis\u2013Activities of Daily Living\">MG-ADL<\/abbr><\/span><span>, and <abbr data-abbreviation-entity=\"10945\" title=\"Myasthenia Gravis Composite\">MGC<\/abbr>) and nonclinical (i.e., patient out-of-pocket cost) attributes influence neurologists\u2019 prescribing decisions. It also identifies the key opportunities in the treatment of generalized MG that will be crucial to the strategic positioning of novel agents in this evolving market.<\/span><\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the most important factors driving neurologists\u2019 prescribing decisions for g<abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr>? Do these factors differ between U.S. and European neurologists?<\/li>\n<li>When considering eculizumab, efgartigimod, ravulizumab, zilucoplan, rozanolixizumab, and nipocalimab, which drug attributes are key influencers, which have limited impact, and which are the hidden opportunities in g<abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in the g<abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr> market?<\/li>\n<li>What trade-offs are surveyed neurologists willing to make across key clinical attributes and price when considering a new <abbr data-abbreviation-entity=\"10277\" title=\"myasthenia gravis\">MG<\/abbr> therapy?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 34 European neurologists fielded in January 2026<\/p>\n<p><strong>Key drugs:<\/strong> Eculizumab, nipocalimab, rozanolixizumab<\/p>\n<p><strong>Key feature: <\/strong>Target Product Profile (<abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-575179","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575179\/revisions"}],"predecessor-version":[{"id":575715,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575179\/revisions\/575715"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=575179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}